Kalaris Therapeutics (NASDAQ:KLRS – Get Free Report) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Monday, Wall Street Zen reports.
Separately, Weiss Ratings upgraded Kalaris Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, November 4th. Six analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $18.75.
Read Our Latest Report on Kalaris Therapeutics
Kalaris Therapeutics Stock Performance
Kalaris Therapeutics (NASDAQ:KLRS – Get Free Report) last posted its earnings results on Tuesday, November 10th. The company reported ($0.46) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.06. Equities analysts predict that Kalaris Therapeutics will post -1.92 EPS for the current year.
Institutional Inflows and Outflows
A number of hedge funds have recently added to or reduced their stakes in the stock. ADAR1 Capital Management LLC bought a new position in Kalaris Therapeutics in the 2nd quarter worth $407,000. BlackRock Inc. bought a new stake in shares of Kalaris Therapeutics during the 2nd quarter valued at about $222,000. Pale Fire Capital SE bought a new stake in shares of Kalaris Therapeutics during the 2nd quarter valued at about $161,000. Stonepine Capital Management LLC purchased a new position in shares of Kalaris Therapeutics during the second quarter valued at about $122,597. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of Kalaris Therapeutics during the second quarter valued at about $122,000. 66.05% of the stock is owned by hedge funds and other institutional investors.
Kalaris Therapeutics Company Profile
Kalaris Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for retinal diseases. Its work centers on advancing investigational therapies intended to address conditions affecting vision. The company’s product candidates are in development and are not approved for commercial use. Kalaris’s activities include research and development and the clinical evaluation of potential therapies. Publicly available information about the company’s leadership and geographic operations is limited.
Featured Articles
- Five stocks we like better than Kalaris Therapeutics
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Kalaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
